MX2009006859A - Formas cristalinas de glyt1. - Google Patents
Formas cristalinas de glyt1.Info
- Publication number
- MX2009006859A MX2009006859A MX2009006859A MX2009006859A MX2009006859A MX 2009006859 A MX2009006859 A MX 2009006859A MX 2009006859 A MX2009006859 A MX 2009006859A MX 2009006859 A MX2009006859 A MX 2009006859A MX 2009006859 A MX2009006859 A MX 2009006859A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- glyt1
- preparation
- present
- methanone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención se refiere a cuatro formas cristalinas distintas y a una forma amorfa de [4-(3-fluor-5-trifluormetil-piri din-2-il)-piperazin-1-il)-[5-metanosulfonil-2-((S)-2,2,2-trifluor -1-metil-etoxi)-fenil]-metanona y a su utilización para la preparación de composiciones farmacéuticas. Los compuestos de la presente invención son adecuados para la preparación de un medicamento destinado al tratamiento de psicosis, dolor, disfunción neurodegenerativa en memoria y aprendizaje, esquizofrenia, demencia y otras enfermedades en las que están desequilibrados los procesos cognitivos, tal como trastornos con déficit de atención o enfermedad de Alzheimer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06127269 | 2006-12-28 | ||
PCT/EP2007/064104 WO2008080821A1 (en) | 2006-12-28 | 2007-12-18 | Crystalline forms glyt1 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009006859A true MX2009006859A (es) | 2009-07-03 |
Family
ID=38988312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009006859A MX2009006859A (es) | 2006-12-28 | 2007-12-18 | Formas cristalinas de glyt1. |
Country Status (33)
Country | Link |
---|---|
US (5) | US20080214561A1 (es) |
EP (1) | EP2114405B1 (es) |
JP (1) | JP4799666B2 (es) |
KR (1) | KR101130146B1 (es) |
CN (1) | CN101573114A (es) |
AR (1) | AR064545A1 (es) |
AU (1) | AU2007341356B2 (es) |
BR (1) | BRPI0720829B8 (es) |
CA (1) | CA2673667A1 (es) |
CL (1) | CL2007003830A1 (es) |
CO (1) | CO6190613A2 (es) |
CR (1) | CR10846A (es) |
CY (1) | CY1116350T1 (es) |
DK (1) | DK2114405T3 (es) |
EC (1) | ECSP099471A (es) |
ES (1) | ES2535040T3 (es) |
HR (1) | HRP20150573T1 (es) |
HU (1) | HUE025032T2 (es) |
MA (1) | MA31029B1 (es) |
MX (1) | MX2009006859A (es) |
MY (1) | MY188367A (es) |
NO (1) | NO342150B1 (es) |
NZ (1) | NZ577502A (es) |
PE (1) | PE20081556A1 (es) |
PL (1) | PL2114405T3 (es) |
PT (1) | PT2114405E (es) |
RS (1) | RS53910B1 (es) |
RU (1) | RU2463295C2 (es) |
SI (1) | SI2114405T1 (es) |
TW (1) | TWI388552B (es) |
UA (1) | UA100232C2 (es) |
WO (1) | WO2008080821A1 (es) |
ZA (1) | ZA200904423B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2114405E (pt) | 2006-12-28 | 2015-06-02 | Hoffmann La Roche | Forma co-cristalina de metil-parabeno ¿a¿ - [4- (3-fluor-5-trifluormetil-piridin-2-il)-piperazin- 1-il]-[5-metano-sulfonil-2-((s)-2,2,2-trifluoro-1- metil-etoxi)-fenil]-metanona |
US8586587B2 (en) | 2009-02-26 | 2013-11-19 | Thar Pharmaceuticals, Inc. | Crystalline molecular complex of tadalafil and methylparaben |
KR101196354B1 (ko) * | 2010-09-03 | 2012-11-01 | 서유헌 | 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물 |
CN104334550A (zh) * | 2012-05-25 | 2015-02-04 | 巴斯夫欧洲公司 | 1,5-二甲基-6-硫代-3-(2,2,7-三氟-3-氧代-4-(丙-2-炔基)-3,4-二氢-2H-苯并[b][1,4]噁嗪-6-基)-1,3,5-三嗪烷-2,4-二酮的晶型B |
US8927412B1 (en) * | 2013-08-01 | 2015-01-06 | Taiwan Semiconductor Manufacturing Company, Ltd. | Multi-chip package and method of formation |
MX354615B (es) * | 2013-10-02 | 2018-03-08 | Centro De Investig Y De Estudios Avanzados Del I P N | Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus. |
CN116212025A (zh) | 2020-01-09 | 2023-06-06 | 迪斯克医药公司 | 治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法 |
JP2024518091A (ja) * | 2021-05-14 | 2024-04-24 | ディスク・メディシン・インコーポレイテッド | グリシン輸送阻害剤を用いて赤血球増殖性プロトポルフィリン症、x連鎖プロトポルフィリン症または先天性赤血球増殖性ポルフィリン症を処置する方法 |
WO2022251458A1 (en) * | 2021-05-27 | 2022-12-01 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL154370A0 (en) | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
SI1656361T1 (sl) * | 2003-08-11 | 2008-04-30 | Hoffmann La Roche | Piperazin z OR-substituirano fenilno skupino in njuna uporaba kot zaviralca GLYT1 |
PT2114405E (pt) | 2006-12-28 | 2015-06-02 | Hoffmann La Roche | Forma co-cristalina de metil-parabeno ¿a¿ - [4- (3-fluor-5-trifluormetil-piridin-2-il)-piperazin- 1-il]-[5-metano-sulfonil-2-((s)-2,2,2-trifluoro-1- metil-etoxi)-fenil]-metanona |
-
2007
- 2007-12-18 PT PT78577343T patent/PT2114405E/pt unknown
- 2007-12-18 HU HUE07857734A patent/HUE025032T2/en unknown
- 2007-12-18 EP EP07857734.3A patent/EP2114405B1/en active Active
- 2007-12-18 MX MX2009006859A patent/MX2009006859A/es active IP Right Grant
- 2007-12-18 UA UAA200907731A patent/UA100232C2/uk unknown
- 2007-12-18 CA CA002673667A patent/CA2673667A1/en not_active Abandoned
- 2007-12-18 WO PCT/EP2007/064104 patent/WO2008080821A1/en active Application Filing
- 2007-12-18 AU AU2007341356A patent/AU2007341356B2/en active Active
- 2007-12-18 PL PL07857734T patent/PL2114405T3/pl unknown
- 2007-12-18 KR KR1020097015643A patent/KR101130146B1/ko active IP Right Grant
- 2007-12-18 SI SI200731644T patent/SI2114405T1/sl unknown
- 2007-12-18 RU RU2009124113/04A patent/RU2463295C2/ru active
- 2007-12-18 RS RS20150229A patent/RS53910B1/en unknown
- 2007-12-18 BR BRPI0720829A patent/BRPI0720829B8/pt active IP Right Grant
- 2007-12-18 CN CNA2007800479512A patent/CN101573114A/zh active Pending
- 2007-12-18 JP JP2009543441A patent/JP4799666B2/ja active Active
- 2007-12-18 DK DK07857734T patent/DK2114405T3/en active
- 2007-12-18 MY MYPI20092584A patent/MY188367A/en unknown
- 2007-12-18 ES ES07857734.3T patent/ES2535040T3/es active Active
- 2007-12-18 NZ NZ577502A patent/NZ577502A/en unknown
- 2007-12-19 US US12/002,997 patent/US20080214561A1/en not_active Abandoned
- 2007-12-25 TW TW096150002A patent/TWI388552B/zh active
- 2007-12-27 CL CL200703830A patent/CL2007003830A1/es unknown
- 2007-12-27 AR ARP070105913A patent/AR064545A1/es not_active Application Discontinuation
-
2008
- 2008-01-02 PE PE2008000055A patent/PE20081556A1/es not_active Application Discontinuation
-
2009
- 2009-06-08 CR CR10846A patent/CR10846A/es unknown
- 2009-06-11 CO CO09061117A patent/CO6190613A2/es not_active Application Discontinuation
- 2009-06-19 NO NO20092358A patent/NO342150B1/no unknown
- 2009-06-24 ZA ZA200904423A patent/ZA200904423B/xx unknown
- 2009-06-26 EC EC2009009471A patent/ECSP099471A/es unknown
- 2009-06-29 MA MA32049A patent/MA31029B1/fr unknown
-
2010
- 2010-07-22 US US12/841,195 patent/US8039473B2/en not_active Expired - Fee Related
-
2011
- 2011-07-22 US US13/188,486 patent/US20110295007A1/en not_active Abandoned
-
2012
- 2012-06-13 US US13/495,093 patent/US20120309969A1/en not_active Abandoned
-
2013
- 2013-03-13 US US13/798,358 patent/US20130197225A1/en not_active Abandoned
-
2015
- 2015-05-20 CY CY20151100451T patent/CY1116350T1/el unknown
- 2015-05-28 HR HRP20150573TT patent/HRP20150573T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009006859A (es) | Formas cristalinas de glyt1. | |
MXPA06002727A (es) | Derivados de 1-(2-amino-benzol)-piperazina como inhibidores de la captacion de glicina para el tratamiento de psicosis. | |
MY145356A (en) | Piperzine with or-substitution for glyt1 | |
TW200505907A (en) | Piperidine-benzenesulfonamide derivatives | |
MX2009011830A (es) | Compuestos amino-heterociclicos. | |
CU20110106A7 (es) | Nuevos compuestos 578 | |
MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
MX2012007013A (es) | Moduladores alostericos positivos de receptores m1 de la quinolina amida. | |
IN2012DN00766A (es) | ||
TW200633957A (en) | Compounds | |
MX2009014001A (es) | Derivados de isoxazol-imidazol. | |
TW200602297A (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
NZ593279A (en) | Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors | |
IL198926A0 (en) | Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition | |
TW200714282A (en) | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | |
MXPA05004273A (es) | Derivados de fenilalquil y piridilalquil piperazina. | |
WO2005095348A3 (en) | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | |
WO2005097114A3 (en) | Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders | |
WO2007034326A3 (en) | Imidazole compounds for the treatment of neurological disorders | |
WO2009134668A3 (en) | 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators | |
GB0428232D0 (en) | Compounds | |
MX2010008239A (es) | 2-aminoquinolinas. | |
IN2009CN03566A (es) | ||
WO2011015646A3 (en) | Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders | |
DE602006015193D1 (de) | 8-alk0xy-4-methyl-3, 4-dihydr0-chinaz0lin-2-yl-amine und ihre verwendung als 5-ht5a-rezeptor-liganden |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |